Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic CancerUnusual Whales·Jul 14 at 06:04 AMCANF-1.24%
11 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Jul 2 at 12:05 PMLIMN-6.57%ELTX-4.76%
Biggest stock movers Thursday: FIZZ, CANF, and morebusinessinsider·Jul 2 at 04:30 AMEMBJ-0.82%FIZZ+0.56%
Can-Fite’s Namodenoson meets primary safety endpoints in Phase IIa trialWorldPharmaceuticals·Jul 2 at 04:22 AMCANF-1.24%
Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watchrttnews·Jul 1 at 10:22 PMCANF-1.24%ELTX-4.76%
Can-Fite BioPharma Soars 56% After Cancer Drug Trial Meets Safety EndpointUS Stock Market Update·Jul 1 at 03:12 PMCANF-1.24%
12 Industrials Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·Jul 1 at 12:05 PMSKIL+2.09%YOOV0.00%
Can-Fite BioPharma (CANF) Soars 52% on Phase 2a Cancer Drug ResultsUS Stock Market Update·Jul 1 at 09:20 AMCANF-1.24%
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patientsbenzinga_article·Jul 1 at 09:13 AMCANF-1.24%
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga_article·Jul 1 at 07:05 AMCANF-1.24%RDHL-5.22%
Can-Fite Biopharma shares are trading higher after the company announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes..benzinga_article·Jul 1 at 07:00 AMCANF-1.24%
Can-Fite BioPharma Falls 9% After Hours as Japan Approves Obesity Drug PatentUS Stock Market Update·Jun 26 at 06:43 PMCANF-1.24%
Can-Fite BioPharma Tumbles 11% in After-Hours Trading to Fresh LowUS Stock Market Update·Jun 26 at 04:21 PMCANF-1.24%
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga_article·Jun 26 at 04:05 PMIRON-2.29%TVRD-1.95%